Pernix Therapeutics Holdings Inc. (PTX) 4.70 $PTX
Pernix Establishes New Corporate Headquarters
Business Wire - Thu Apr 17, 9:59AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced it has signed a lease for new corporate headquarters at 10 North Park Place in Morristown, NJ.
Super Stock Profits - Top Five Stocks in Focus: Constant Contact, Inc. Av Works Aviation Corporation, Pixelworks, Inc. Fannie Mae, Pernix Therapeutics Holdings
PR Newswire Europe - Thu Apr 10, 9:49AM CDT
LONDON, April 10, 2014 /PRNewswire/ --
Pernix Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 8:34AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that Pernix CEO Doug Drysdale is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 12:50 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector.
Pernix expects USD6.2m in net proceeds and annual cost savings from Pernix Manufacturing LLC's sale
M2 - Wed Apr 02, 5:28AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKT
TX) said on Tuesday that it has entered into a definitive agreement to sell its Houston, TX-based manufacturing operations, Pernix Manufacturing LLC (PML).
Pernix Agrees to Divest Manufacturing Facility
Business Wire - Tue Apr 01, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKTTX), a specialty pharmaceutical company, today announced that it has signed a definitive agreement to divest its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML" to Woodfield Pharmaceutical LLC ("Woodfield".
Health Care Stocks on our Radar -- Research on Novo Nordisk, Tianyin Pharma, Pernix Therapeutics Holdings, and Oculus Innovative Sciences
PR Newswire - Wed Mar 26, 12:10PM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite finished at 4,234.27, up 0.19%. The Dow Jones Industrial Average closed the session at 16,367.88, up 0.56% and the S&P 500 ended the day at 1,865.62, higher by 0.44%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, and the same has gained 5.27% in the previous three months. Investor-Edge has initiated coverage on the following equities: Novo Nordisk A/S (NYSE: NVO), Tianyin Pharmaceutical Co. Inc. (NYSE MKT: TPI), Pernix Therapeutics Holdings (NASDAQ: PTX) and Oculus Innovative Sciences Inc. (NASDAQ: OCLS). Free technical research on NVO, TPI, PTX and OCLS can be downloaded upon signing up at:
Commit To Purchase Pernix Therapeutics Holdings At $5, Earn 24.1% Annualized Using Options
StockOptionsChannel.com - Tue Mar 25, 11:19AM CDT
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $5.66/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Pernix Therapeutics Appoints Senior Vice President of Sales and Marketing
Business Wire - Tue Mar 18, 9:35AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company" (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Rick Shalaby as Senior Vice President of Sales and Marketing effective March 17, 2014.
Pernix Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Mon Mar 17, 7:01AM CDT
--Quarter over Quarter Revenue Increased by 31.5% to $24 Million
Pernix Therapeutics Appoints John Sedor to Its Board of Directors
Business Wire - Thu Mar 13, 11:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of John Sedor as a non-executive Director and Chairman of the Compensation Committee of its Board of Directors. Mr. Sedor has more than 30 years of proven leadership in the global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. John is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise. Prior to his current role as President and CEO at Rodes Inc., John most recently served as President, CEO and Director of Cangene Corporation, one of the world's leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.
Pernix Therapeutics appoints Terence Novak as COO
M2 - Tue Mar 11, 6:24AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NasdaqGMTX) disclosed on Monday that Terence Novak has been elected as its chief operating officer.
Pernix Therapeutics Appoints Chief Operating Officer
Business Wire - Mon Mar 10, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of Terence Novak as Chief Operating Officer.
Pernix Therapeutics Appoints Vice President of Compliance
Business Wire - Tue Mar 04, 7:30AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of Jessica Oien as Vice President of Compliance.
Pernix to Market Osmotica's Khedezla - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 4:30PM CST
Pernix Therapeutics Holdings recently announced that it has signed an agreement with the privately-held Osmotica Pharmaceuticals Corp. to market major depressive disorder (MDD) drug Khedezla.
Pernix Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014
Business Wire - Mon Mar 03, 7:30AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its fourth quarter and full year 2013 financial results before the U.S. stock market opens on Monday, March 17, 2014 and has scheduled a conference call at 9:00 a.m. EDT that day to discuss the financial results.
Pernix Signs Agreement with Osmotica Pharmaceutical Corp to Promote KHEDEZLA (Desvenlafaxine ER) Tablets, 50 mg and 100 mg for Major Depressive Disorder
Business Wire - Thu Feb 27, 12:07PM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company", a specialty pharmaceutical company, today announced that it has signed an agreement with Osmotica Pharmaceuticals Corp ("Osmotica" to market and sell KHEDEZLA(TM) (desvenlafaxine) Extended-Release (ER) Tablets, 50 mg and 100 mg. The sales and marketing of KHEDEZLA will be supported by Pernix's team of approximately 90 sales professionals, promoting the product to high desvenlafaxine prescribing physicians. The New Drug Application (NDA) for KHEDEZLA Tablets was approved by the U.S. Food and Drug Administration pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act in July 2013. KHEDEZLA is indicated for the treatment of major depressive disorder (MDD).
Pernix Closes $65 Million Institutional Investment; Amends MidCap Revolver; Moves to Reshape Board of Directors
Business Wire - Mon Feb 24, 7:31AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company", a specialty pharmaceutical company, today announced that it has closed on the issuance of $65 million aggregate principal amount of 8.00% Convertible Senior Notes due 2019 (the "Notes" to a group of institutional investors led by Athyrium Capital Management, providing the Company with expansion capital for the acquisition of accretive specialty products to be added to the Company's portfolio, as well as for working capital and general corporate purposes.
Biotech Winners: Pernix, Myriad, Repros, OraSure
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 06, 7:40PM CST
In this video from Thursday's Market Checkup , Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today. In this segment, a look at some big winners during...
Pernix Appoints New CEO, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 3:35PM CST
Shares of Pernix Therapeutics Holdings, Inc. (PTX) jumped 68.9% on the back of an institutional investment by Athyrium Capital Management and the appointment of a new Chief Executive Officer (CEO).
Pernix Establishes New Corporate Headquarters
Business Wire - Thu Apr 17, 9:59AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced it has signed a lease for new corporate headquarters at 10 North Park Place in Morristown, NJ. Super Stock Profits - Top Five Stocks in Focus: Constant Contact, Inc. Av Works Aviation Corporation, Pixelworks, Inc. Fannie Mae, Pernix Therapeutics Holdings
PR Newswire Europe - Thu Apr 10, 9:49AM CDT
LONDON, April 10, 2014 /PRNewswire/ --
Pernix Therapeutics to Present at the 13th Annual Needham Healthcare Conference
Business Wire - Wed Apr 02, 8:34AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced that Pernix CEO Doug Drysdale is scheduled to present at the 13th Annual Needham Healthcare Conference in New York City on Wednesday, April 9, 2014, at 12:50 p.m. ET. The Needham Healthcare Conference is considered to be one of the best venues for leading life science and medical technology companies, and the institutions who invest in the sector. Pernix expects USD6.2m in net proceeds and annual cost savings from Pernix Manufacturing LLC's sale
M2 - Wed Apr 02, 5:28AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NASDAQ MKT
TX) said on Tuesday that it has entered into a definitive agreement to sell its Houston, TX-based manufacturing operations, Pernix Manufacturing LLC (PML). Pernix Agrees to Divest Manufacturing Facility
Business Wire - Tue Apr 01, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKTTX), a specialty pharmaceutical company, today announced that it has signed a definitive agreement to divest its Houston, TX-based manufacturing operations, Pernix Manufacturing, LLC ("PML" to Woodfield Pharmaceutical LLC ("Woodfield". Health Care Stocks on our Radar -- Research on Novo Nordisk, Tianyin Pharma, Pernix Therapeutics Holdings, and Oculus Innovative Sciences
PR Newswire - Wed Mar 26, 12:10PM CDT
On Tuesday, March 25, 2014, the NASDAQ Composite finished at 4,234.27, up 0.19%. The Dow Jones Industrial Average closed the session at 16,367.88, up 0.56% and the S&P 500 ended the day at 1,865.62, higher by 0.44%. The gains were broad based with nine out of ten sectors ending the session in positive. The S&P 500 Health Care Sector Index finished the day at 671.69, up 0.83%, and the same has gained 5.27% in the previous three months. Investor-Edge has initiated coverage on the following equities: Novo Nordisk A/S (NYSE: NVO), Tianyin Pharmaceutical Co. Inc. (NYSE MKT: TPI), Pernix Therapeutics Holdings (NASDAQ: PTX) and Oculus Innovative Sciences Inc. (NASDAQ: OCLS). Free technical research on NVO, TPI, PTX and OCLS can be downloaded upon signing up at:
Commit To Purchase Pernix Therapeutics Holdings At $5, Earn 24.1% Annualized Using Options
StockOptionsChannel.com - Tue Mar 25, 11:19AM CDT
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $5.66/share, might benefit from considering selling puts among the alternative strategies at their disposal.
Pernix Therapeutics Appoints Senior Vice President of Sales and Marketing
Business Wire - Tue Mar 18, 9:35AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"
(NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Rick Shalaby as Senior Vice President of Sales and Marketing effective March 17, 2014. Pernix Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Mon Mar 17, 7:01AM CDT
--Quarter over Quarter Revenue Increased by 31.5% to $24 Million
Pernix Therapeutics Appoints John Sedor to Its Board of Directors
Business Wire - Thu Mar 13, 11:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of John Sedor as a non-executive Director and Chairman of the Compensation Committee of its Board of Directors. Mr. Sedor has more than 30 years of proven leadership in the global pharmaceutical, biopharmaceutical, consumer product and generic drug industries. John is recognized for his entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise. Prior to his current role as President and CEO at Rodes Inc., John most recently served as President, CEO and Director of Cangene Corporation, one of the world's leading biopharmaceutical companies in the development, manufacture and commercialization of therapies targeting infectious disease, hematology/oncology and transplantation. Under his guidance, Cangene was acquired by Emergent BioSolutions in February 2014. Prior to joining Cangene, he served as President, CEO and Director of CPEX Pharmaceuticals, Inc., a specialty drug delivery pharmaceutical company, and managed its spin-off from Bentley Pharmaceuticals, Inc. Prior to that, he was President of Bentley, which expanded its nanotechnology programs and added more than 20 new product approvals in the European market under his leadership. In 1996, John created Centeon LLC to develop and commercialize plasma protein biotherapeutics. Other previous roles include President of Sandoz Inc. (Novartis), and various senior positions at Verion, Rorer Pharmaceutical Co., Revlon Health Care Group and Armour Pharmaceutical Company.
Pernix Therapeutics appoints Terence Novak as COO
M2 - Tue Mar 11, 6:24AM CDT
Pharmaceutical company Pernix Therapeutics Holdings (NasdaqGM
TX) disclosed on Monday that Terence Novak has been elected as its chief operating officer. Pernix Therapeutics Appoints Chief Operating Officer
Business Wire - Mon Mar 10, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of Terence Novak as Chief Operating Officer.
Pernix Therapeutics Appoints Vice President of Compliance
Business Wire - Tue Mar 04, 7:30AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced the appointment of Jessica Oien as Vice President of Compliance.
Pernix to Market Osmotica's Khedezla - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 4:30PM CST
Pernix Therapeutics Holdings recently announced that it has signed an agreement with the privately-held Osmotica Pharmaceuticals Corp. to market major depressive disorder (MDD) drug Khedezla.
Pernix Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014
Business Wire - Mon Mar 03, 7:30AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, today announced that it will release its fourth quarter and full year 2013 financial results before the U.S. stock market opens on Monday, March 17, 2014 and has scheduled a conference call at 9:00 a.m. EDT that day to discuss the financial results.
Pernix Signs Agreement with Osmotica Pharmaceutical Corp to Promote KHEDEZLA (Desvenlafaxine ER) Tablets, 50 mg and 100 mg for Major Depressive Disorder
Business Wire - Thu Feb 27, 12:07PM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"
, a specialty pharmaceutical company, today announced that it has signed an agreement with Osmotica Pharmaceuticals Corp ("Osmotica" to market and sell KHEDEZLA(TM) (desvenlafaxine) Extended-Release (ER) Tablets, 50 mg and 100 mg. The sales and marketing of KHEDEZLA will be supported by Pernix's team of approximately 90 sales professionals, promoting the product to high desvenlafaxine prescribing physicians. The New Drug Application (NDA) for KHEDEZLA Tablets was approved by the U.S. Food and Drug Administration pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act in July 2013. KHEDEZLA is indicated for the treatment of major depressive disorder (MDD). Pernix Closes $65 Million Institutional Investment; Amends MidCap Revolver; Moves to Reshape Board of Directors
Business Wire - Mon Feb 24, 7:31AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"
, a specialty pharmaceutical company, today announced that it has closed on the issuance of $65 million aggregate principal amount of 8.00% Convertible Senior Notes due 2019 (the "Notes" to a group of institutional investors led by Athyrium Capital Management, providing the Company with expansion capital for the acquisition of accretive specialty products to be added to the Company's portfolio, as well as for working capital and general corporate purposes. Biotech Winners: Pernix, Myriad, Repros, OraSure
David Williamson and Max Macaluso, The Motley Fool - Motley Fool - Thu Feb 06, 7:40PM CST
In this video from Thursday's Market Checkup , Motley Fool health-care analysts David Williamson and Max Macaluso dive into the biggest stories impacting health-care investors on the market today. In this segment, a look at some big winners during...
Pernix Appoints New CEO, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 3:35PM CST
Shares of Pernix Therapeutics Holdings, Inc. (PTX) jumped 68.9% on the back of an institutional investment by Athyrium Capital Management and the appointment of a new Chief Executive Officer (CEO).
